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Spinal anesthesia, referred to as “cocainization of 
the spinal cord” in early 1900s [1] has now 
become one of the most commonly used 
techniques for regional anesthesia in obstetric 
surgeries worldwide. It is preferred over general 
anesthesia as it is associated with reduced 
maternal mortality, more direct experience of 
childbirth, and faster neonatal-maternal bonding. 
[2] In England, for example, regional anesthesia 
was used for caesarean section in about 40% of 
cases in 2008/9 compared to 5% using general 
anesthesia [3]. 
Bupivacaine is an amide type local anesthetic, a 
racemic (50:50) mixture of S and R enantiomers 
[4]. Since its introduction in 1956, it has been 
used as the drug of choice for spinal anesthesia 
due to its longer duration of action (3-7 hours), 
limited placental transfer, and minimal neonatal 
effects compared to other local anesthetics [4]. In 
1979, attention was drawn towards the 
cardiotoxic and neurotoxic effects of 
bupivacaine, linked to its R-enantiomer [5]. As a 
result, another amide type local anesthetic, 
ropivacaine, the S-enantiomer of propyl 
derivative of pipecoloxylidide was first 
introduced in 1996 and approved for spinal 
anesthesia in the European Union in 2004 [6]. 
Ropivacaine, being a pure S-enantiomer, has low 
lipid solubility and blocks nerve fibres involved 
in pain transmission to a greater degree than 
those involved in motor function [7]. 
The report by Singh et al [8] in this issue of 
JPMS adds to the overall evidence that there is a 
greater degree of sensory-motor separation with 
ropivacaine as compared to bupivacaine. Singh et 
al compared the efficacy of intrathecal 0.75% 
isobaric ropivacaine (24 mg) with 0.5% heavy 
bupivacaine (12.5 mg) for elective caesarean 
section. Safety of these two drugs was also 
assessed as a secondary outcome. A total of 46 
parturients were enrolled in this single-blind, 
randomized controlled trial.  
The main findings were that bupivacaine had a 
shorter time to achieve sensory block at T10 
(2.5±1.3 min) compared to ropivacaine (3.2±1.5 
min) (p <0.05). The time taken for maximal 
block was also significantly lower (p <0.05) in 
bupivacaine group (7.9±2.3 min) in comparison 
to ropivacaine group (9.8±3.1 min). However, the 
duration of motor block was significantly shorter 
(p <0.01) in ropivacaine group (112.5±45) as 
compared to bupivacaine group (165.3±26). This 
finding is consistent with previous literature that 
ropivacaine provides spinal anesthesia of similar 
quality to that of bupivacaine with shorter 
duration of motor block [7]. 
However, there are concerns regarding the 
adverse clinical outcome evaluated in this study.  
The authors also reported significantly fewer 
side-effects (p <0.05) such as hypotension, 
nausea, shivering and bradycardia in the 
ropivacaine group than bupivacaine group. Since 
the trial was not double-blinded, there is a high 
potential for observer bias. Therefore, due to the 
nature of blinding in the trial and a very small 
number of events in both the groups, it is difficult 
to conclude that the safety profile of ropivacaine 
is superior to bupivacaine. Additionally, the 
study also concludes that there was no statistical 
difference between APGAR scores in the two 
groups. This seems an encouraging finding; 
however, it may be confounded by vasopressor 
administration and hypotension episodes, which 
were significantly different in both drug groups 
and may have altered the true association 
between the drugs and APGAR scores. 
 When comparing drugs for spinal anesthesia, 
three factors are essential to assess – the speed of 
onset, quality of block and the cost. In this 
particular study, the onset of block was shorter in 
bupivacaine than ropivacaine. However, in 
context of elective caesarean delivery, this may 
not be clinically important. It may be more 
important in emergency cases, where there is 
urgency to deliver the fetus. Nevertheless, the 
magnitude of difference found in the study is so 
small that it is difficult to say that one is better 
than the other. Likewise, none of the parturients 
required conversion to general anesthesia and 
adequate level of sensory analgesia and complete 
motor block was achieved in all patients. 
Therefore, the quality of block was comparable 
between both groups. The only important 
difference between both groups was the duration 
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of motor block. This finding favors the use of 
ropivacaine, as shorter motor block would mean 
early mobilization, shorter time to first micturation 
and earlier recovery from respiratory disturbance 
caused by spinal anesthesia [9]. Therefore, from a 
clinical perspective, both the drugs are comparable 
and can be used for spinal anesthesia.  
Lastly, cost-effectiveness of the drug is another 
practical issue to be considered. In the UK, for 
example, the cost of the chosen dose of ropivacaine 
is 3 times higher than the cost of bupivacaine [10]. 
This may be an important factor in the clinical 
applicability and use of ropivacaine especially in 
developing countries. Therefore, from an economic 
perspective, it is difficult to justify the use of 
ropivacaine in place of bupivacaine when both the 
drugs have very similar clinical effects. It is well 
established now that ropivacaine has very similar 
sensory effects but offers a shorter motor block than 
bupivacaine. What is needed now is an economic 
analysis to investigate which drug is more cost-
effective in elective obstetric and other surgeries.   
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